Aurobindo to Bolster Generics Portfolio with US$1 B Sandoz Deal
By Michelle Liu & Keval Haria
Pharma Deals Review: Vol 2018 Issue 9 (Table of Contents)
Published: 14 Sep-2018
DOI: 10.3833/pdr.v2018.i9.2358 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Novartis has agreed to sell its Sandoz US dermatology business and generic oral solids to Indian generics company, Aurobindo Pharma, in a deal potentially worth up to US$1 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS